CoChat

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review

Open access

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Abstract

Background and Objectives: The association between diabetes mellitus and increased risk of bone fractures has led to the investigation of the impact of antidiabetic drugs on bone metabolism. Glucagon-like peptide-1 receptor agonists (GLP1RAs) are a relatively novel and promising class of anti-hyperglycemic drugs. In addition to their blood glucose lowering action, GLP1RAs seem to have additional pleiotropic properties such as a beneficial skeletal effect; although the underlying mechanisms are not completely understood. The present systematic review summarizes current evidence about GLP1RAs and their effects on bone metabolism and fracture. Methods: An extensive literature search was conducted based on electronic databases namely, PubMed, Google Scholar and Cochrane Central Register of Controlled Trials (CENTRAL) through October 2019 to January 2020 for articles related to bone mineral density, diabetes mellitus and GLP1RAs. We included articles published in English. Finally, we included four randomized controlled trials, three meta-analyses, a case-control study and a population-based cohort analysis. Results: Based on the articles included, the animal studies indicated the salutary skeletal effects of GLP1RAs in opposition to what has been commonly observed in human studies, showing that these agents have no impact on bone mineral density (BMD) and the turnover markers. Moreover, it was demonstrated that GLP1 was not associated with fracture risk as compared to other anti-hyperglycemic drugs. Conclusions: Findings from this systematic review have demonstrated the neutral impact of GLP1RAs on BMD. Moreover, further double-blind randomized controlled trials are needed to draw more meaningful and significant conclusions on the efficacy of GLP1RAs on BMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/medicina58020224

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RANKL is an osteoclast differentiation factor. This factor binds to the RANK receptor in primary osteoclast cells and leads to differentiation and activation of osteoclasts. RANK enhances the action of osteoclast while OPG binds to RANKL and therefore inhibits bone resorption. An imbalance of OPG/RANKL/RANK expression is responsible for osteoporosis [6] (Legend: IL: Interleukins, IFNγ: Interferon gamma, PTH: Parathormone, T4: Thyroxine, Vit D: Vitamin D, PDGF: Platelet-Derived Growth Factor, OPG: Osteoprotegerin, RANKL: Receptor activator of nuclear factor kappa-Β ligand, M-CSF: Macrophage colony stimulating factor. Blue arrows imply production; red arrows imply inhibition; green arrows imply stimulation) (T-Cell is reproduced under CC BY 3.0 License from https://en.wikipedia.org/wiki/T_cell#/media/File:Blausen_0625_Lymphocyte_T_cell_(crop).png. Bone cells are reproduced under the CC BY 3.0 License from https://en.wikipedia.org/wiki/Bone#/media/File:604_Bone_cells.jpg. Vein is reproduced under the CC BY-SA 3.0 License from https://en.wikipedia.org/wiki/Vein#/media/File:Vein_(retouched).svg. All images last accessed on 26 September 2020).
Figure 1 RANKL is an osteoclast differentiation factor. This factor binds to the RANK receptor in primary osteoclast cells and leads to differentiation and activation of osteoclasts. RANK enhances the action of osteoclast while OPG binds to RANKL and therefore inhibits bone resorption. An imbalance of OPG/RANKL/RANK expression is responsible for osteoporosis [6] (Legend: IL: Interleukins, IFNγ: Interferon gamma, PTH: Parathormone, T4: Thyroxine, Vit D: Vitamin D, PDGF: Platelet-Derived Growth Factor, OPG: Osteoprotegerin, RANKL: Receptor activator of nuclear factor kappa-Β ligand, M-CSF: Macrophage colony stimulating factor. Blue arrows imply production; red arrows imply inhibition; green arrows imply stimulation) (T-Cell is reproduced under CC BY 3.0 License from https://en.wikipedia.org/wiki/T_cell#/media/File:Blausen_0625_Lymphocyte_T_cell_(crop).png. Bone cells are reproduced under the CC BY 3.0 License from https://en.wikipedia.org/wiki/Bone#/media/File:604_Bone_cells.jpg. Vein is reproduced under the CC BY-SA 3.0 License from https://en.wikipedia.org/wiki/Vein#/media/File:Vein_(retouched).svg. All images last accessed on 26 September 2020).CC BY · PubMed Central
Figure 2 The mechanism of GLP1 and GLP1A in bone formation: GLP1 or GLP1A bind to GLP1R. The complex activates PI3K and PKA, which subsequently phosphorylates (P) AKT, PKA as well as P38, ERK1/2 and JNK. AKT enters the nucleus and regulates gene transcription. In addition, PKA induces β-catenin, which also enters the nucleus through the Wnt/β-catenin pathway. Similarly, phosphorylated P38, JNK and ERK1/2 enter the nucleus. All transcription factors facilitate gene expression, which leads to the induction of bone formation (Legend: GLP1: Glucagon-like peptide 1, GLP1A: Glucagon-like peptide 1 agonist, GLP1R: Glucagon-like peptide 1 receptor, GS: G-Proteins, cAMP: cyclic AMP, PI3K: Phosphoinositide 3-kinases, PKA: Protein kinase A, P38: p38 mitogen-activated protein kinase, ERK1/2: extracellular signal-regulated kinases, JNK: c-Jun N-terminal kinase, RUNX2: Runt-related transcription factor 2, SP7: Transcription factor Sp7, OPN: Osteopontin, ALP: Alkaline phosphatase, OPG: Osteoprotegerin, BGLAP: Osteocalcin gene, COL1: Type-1 collagen. Reproduced from Xie et al. (2021) [9] under the Creative Common License CC BY 3.0 link: https://www.frontiersin.org/articles/10.3389/fphar.2021.697442/full, accessed on 28 January 2022).
Figure 2 The mechanism of GLP1 and GLP1A in bone formation: GLP1 or GLP1A bind to GLP1R. The complex activates PI3K and PKA, which subsequently phosphorylates (P) AKT, PKA as well as P38, ERK1/2 and JNK. AKT enters the nucleus and regulates gene transcription. In addition, PKA induces β-catenin, which also enters the nucleus through the Wnt/β-catenin pathway. Similarly, phosphorylated P38, JNK and ERK1/2 enter the nucleus. All transcription factors facilitate gene expression, which leads to the induction of bone formation (Legend: GLP1: Glucagon-like peptide 1, GLP1A: Glucagon-like peptide 1 agonist, GLP1R: Glucagon-like peptide 1 receptor, GS: G-Proteins, cAMP: cyclic AMP, PI3K: Phosphoinositide 3-kinases, PKA: Protein kinase A, P38: p38 mitogen-activated protein kinase, ERK1/2: extracellular signal-regulated kinases, JNK: c-Jun N-terminal kinase, RUNX2: Runt-related transcription factor 2, SP7: Transcription factor Sp7, OPN: Osteopontin, ALP: Alkaline phosphatase, OPG: Osteoprotegerin, BGLAP: Osteocalcin gene, COL1: Type-1 collagen. Reproduced from Xie et al. (2021) [9] under the Creative Common License CC BY 3.0 link: https://www.frontiersin.org/articles/10.3389/fphar.2021.697442/full, accessed on 28 January 2022).CC BY · PubMed Central
Figure 3 The balance between osteoblast and osteoclast functions: GLP1 induces MSC differentiation to osteoblasts, through the MAPK pathway. Osteocytes, produce sclerostin, which is inhibited by GLP1. Normally, stimulated osteoblasts produce MCSF, RANKL and OPG, which stimulate osteoclast precursors in order to retain bone formation balance (i.e., osteoblast and osteoclast functions remain equilibrated). GLP1 induces MAPK and osteoblast function as well as inhibits osteoclast function through the calcitonin-dependent pathway (Legend: GLP1: Glucagon-like peptide 1, MSC: Mesenchymal Stem Cells, MAPK mitogen-activated protein kinase, MCSF: macrophage colony stimulating factor, RANKL: Receptor activator of nuclear factor kappa-Β ligand, OPG: Osteoprotegerin. Green arrows imply stimulation; red arrows imply inhibition; black arrows imply cellular stimulation) (Inspired and reproduced from Schiellerup et al. (2019) [21] under the Creative Common License CC BY 3.0, link: https://www.frontiersin.org/articles/10.3389/fendo.2019.00075/full, accessed on 28 January 2022. MSC is reproduced under CC BY 3.0 License from https://en.wikipedia.org/wiki/Mesenchymal_stem_cell, Osteoblast is reproduced under the CC BY 3.0 License from https://en.wikipedia.org/wiki/Osteoblast, Osteoclast is reproduced under the CC BY-SA 3.0 License from https://en.wikipedia.org/wiki/Osteoclast, Osteocytes are reproduced from https://en.wikipedia.org/wiki/Osteocyte. All images last accessed on 24 January 2022).
Figure 3 The balance between osteoblast and osteoclast functions: GLP1 induces MSC differentiation to osteoblasts, through the MAPK pathway. Osteocytes, produce sclerostin, which is inhibited by GLP1. Normally, stimulated osteoblasts produce MCSF, RANKL and OPG, which stimulate osteoclast precursors in order to retain bone formation balance (i.e., osteoblast and osteoclast functions remain equilibrated). GLP1 induces MAPK and osteoblast function as well as inhibits osteoclast function through the calcitonin-dependent pathway (Legend: GLP1: Glucagon-like peptide 1, MSC: Mesenchymal Stem Cells, MAPK mitogen-activated protein kinase, MCSF: macrophage colony stimulating factor, RANKL: Receptor activator of nuclear factor kappa-Β ligand, OPG: Osteoprotegerin. Green arrows imply stimulation; red arrows imply inhibition; black arrows imply cellular stimulation) (Inspired and reproduced from Schiellerup et al. (2019) [21] under the Creative Common License CC BY 3.0, link: https://www.frontiersin.org/articles/10.3389/fendo.2019.00075/full, accessed on 28 January 2022. MSC is reproduced under CC BY 3.0 License from https://en.wikipedia.org/wiki/Mesenchymal_stem_cell, Osteoblast is reproduced under the CC BY 3.0 License from https://en.wikipedia.org/wiki/Osteoblast, Osteoclast is reproduced under the CC BY-SA 3.0 License from https://en.wikipedia.org/wiki/Osteoclast, Osteocytes are reproduced from https://en.wikipedia.org/wiki/Osteocyte. All images last accessed on 24 January 2022).CC BY · PubMed Central
Figure 4 Flow chart of study selection.BMD: Bone Mineral Density.
Figure 4 Flow chart of study selection.BMD: Bone Mineral Density.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 54 references

Cited by

See all 74

Metadata

Authors
Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N.
Affiliations
  • University of West Attica (GR)
  • Choremeio Research Laboratory, First Department of Pediatrics, National and Kapodistrian University of Athens, Thivon & Levadeias 8, 11527 Athens, Greece
  • Athens Naval & Veterans Hospital (GR)
Corresponding author
  • Vlachou, Eugenia
  • Tsartsalis, Athanasios N.
Venue
Medicina
Publisher
MDPI AG
Published
2022-02-02
Volume
58
Issue
2
Pages
224
ISSN
  • 1010-660X (ISSN-L)
  • 1648-9144
OpenAlex
W4210692687
Cited by
74
References
55
Citations by year
2026: 18 · 2025: 32 · 2024: 19 · 2023: 3 · 2022: 2
FWCI
3.06
Type
journal article
Language
en
Open access
Locations
  • Medicina (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
GLP-1 receptor agonists, bone metabolism, bone mineral density, fracture risk, diabetes mellitus, antidiabetic drugs, bone turnover markers, animal studies
MeSH terms
Animals, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Case-Control Studies, Randomized Controlled Trials as Topic, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. https://app.cochat.ai/papers/10.3390/medicina58020224
The paper
Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N. (2022). The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. Medicina. https://doi.org/10.3390/medicina58020224

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.